Actively Recruiting
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Led by AstraZeneca · Updated on 2026-04-22
1400
Participants Needed
21
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI/TRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life. The iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations
CONDITIONS
Official Title
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with COPD at least 12 months before baseline as assessed by their physician or documented in medical records
- Male or female patients aged over 30 years and under 80 years at enrollment
- Patients prescribed Breztri/Trixeo (BGF) according to local labeling and reimbursement criteria but not yet started on treatment
- Patients able and willing to read, understand, and complete study questionnaires
- Patients providing written informed consent before study inclusion
You will not qualify if you...
- Patients with COPD caused by documented alpha-1 antitrypsin deficiency
- Patients with major cardiac or pulmonary events requiring hospitalization within the last 3 months
- Patients treated with triple fixed-dose combination therapies within 12 months before screening or multiple inhaled triple therapy within 3 months before screening
- Patients hospitalized for COPD exacerbations within 30 days before enrollment
- Pregnant, breastfeeding, or lactating women
- Patients with current diagnosis of asthma, active tuberculosis, lung cancer or metastasis, significant bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases, or other active significant lung diseases
- Patients participating in other observational studies that may interfere or in interventional trials within 30 days before enrollment
- Patients with unresolved respiratory infections including COVID-19 within 30 days before starting BGF and those with persistent long-COVID symptoms
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Research Site
Alexandria, Egypt
Actively Recruiting
2
Research Site
Cairo, Egypt
Actively Recruiting
3
Research Site
Cairo, Egypt
Not Yet Recruiting
4
Research Site
Jawa Barat, Indonesia, Indonesia
Actively Recruiting
5
Research Site
Jakarta, Indonesia
Not Yet Recruiting
6
Research Site
Amman, Jordan
Actively Recruiting
7
Research Site
Kuala Selangor, Malaysia, Malaysia
Actively Recruiting
8
Research Site
Abhā, Saudi Arabia
Actively Recruiting
9
Research Site
Riyadh, Saudi Arabia
Actively Recruiting
10
Research Site
Riyadh, Saudi Arabia
Not Yet Recruiting
11
Research Site
Yunlin, Taiwan, Taiwan
Actively Recruiting
12
Research Site
Taichung, Taiwan
Actively Recruiting
13
Research Site
Tainan, Taiwan
Actively Recruiting
14
Research Site
Taipei, Taiwan
Actively Recruiting
15
Research Site
Bangkok, Thailand
Not Yet Recruiting
16
Research Site
Nonthaburi, Thailand
Actively Recruiting
17
Research Site
Dubai, United Arab Emirates
Not Yet Recruiting
18
Research Site
Dubai, United Arab Emirates
Actively Recruiting
19
Research Site
Hà Nội, Vietnam, Vietnam
Actively Recruiting
20
Research Site
Hà Nội, Vietnam, Vietnam
Not Yet Recruiting
21
Research Site
Ho Chi Minh City, Vietnam
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here